ReCode Therapeutics

1140 O'Brien Drive
Menlo Park, CA 94025
United States

Tel: 408-585-1700

Email: info@recodetx.com

Featured Employer
Show jobs for this employer

About ReCode Therapeutics

The Why Behind Our Work

We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.

Therapeutic Areas of Focus

Cystic fibrosis

Primary ciliary dyskinesia

Certain cancers and central nervous system (CNS) diseases

Power the Next Wave of Genetic Medicine

We are one of the rare companies whose innovations are poised to fundamentally shift an entire class of medicine.

Join us as we advance our pipeline into clinical development and scale ReCode’s next-generation genetic medicines delivery platform and pipeline.

64 articles about ReCode Therapeutics

  • ReCode Therapeutics™, a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, announced that members of the executive team will be participating in three upcoming virtual investor conferences.

  • ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.

  • ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO

  • - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC - Brandon Wustman, Ph.D. promoted to Senior Vice President, R&D MENLO PARK, Calif. & DALLAS--( BUSINESS WIRE )-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for life-limiting respiratory diseases, today announced two key executive appointments. Mu